Annual report pursuant to Section 13 and 15(d)

Merger (Details)

v3.20.4
Merger (Details)
12 Months Ended
Nov. 05, 2020
Director
Right
Milestone
$ / shares
shares
Dec. 31, 2020
Milestone
$ / shares
shares
Nov. 19, 2020
shares
Jun. 29, 2020
shares
Dec. 31, 2019
$ / shares
shares
Merger Information [Abstract]          
Common stock issued (in shares) 7,091,878        
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001     $ 0.0001
Common stock issued (in shares)   10,882,495     2,852,485
Exchange ratio 1.0565 1.0565      
Number of directors required to complete transaction | Director 1        
Contingent Value Rights Agreement [Abstract]          
Contingent value rights payment period   15 years      
Sum of cash consideration paid by a third party 75.00%        
Parent IP deal period   10 years      
Number of milestones accrued | Milestone 0 0      
Number of potential milestones | Milestone 0 0      
Securities Purchase Agreement [Member]          
Merger Information [Abstract]          
Common stock issued (in shares) 3,749,992   3,749,992 1,249,996  
Former stockholders and Optionholders of Private Ocuphire [Member]          
Merger Information [Abstract]          
Percentage ownership 86.60%        
Rexahn [Member]          
Merger Information [Abstract]          
Percentage ownership 13.40%        
Contingent Value Rights Agreement [Abstract]          
Number of contingent value right received per common stock | Right 1        
Rexahn [Member] | BioSense Global LLC [Member]          
Contingent Value Rights Agreement [Abstract]          
Percentage of payments received by Rexahn or its affiliates 90.00%        
Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member]          
Contingent Value Rights Agreement [Abstract]          
Percentage of payments received by Rexahn or its affiliates 90.00%